Key risks
- High PE ratio (49.14) suggests expensive valuation; verify if consolidated revenue growth (+23.5% YoY) and runway justify this multiple
- Standalone segment persistently unprofitable (OPM -11.64% to -28.56% across all quarters), eroding group returns; clarify if this represents turnaround opportunity or structural drag
- Consolidated OPM thin at 4.03%; verify whether pharmacy retail industry structurally operates at low margins or if Entero lags on cost efficiency
- ROE 6.74% trails typical cost of capital; verify if this reflects capex-heavy growth phase or persistent margin constraints
Generated analysis · source review pending